Imetelstat (Rytelo; Geron Corporation) was approved by the FDA on June 6, 2024, as a treatment for transfusion-dependent anemia in patients with lower-risk MDS who have not responded to, lost response to, or are ineligible for ESAs. The Institute for Clinical and Economic Review (ICER) conducted a systematic literature review and cost-effectiveness analysis to evaluate the clinical and economic outcomes of imetelstat for anemia in lower-risk MDS. This report presents a summary of our findings and highlights the key policy recommendation discussed at the California Technology Assessment Forum (CTAF) public meeting on July 19, 2024. The full report is available at: https://icer.org/wpcontent/uploads/2024/08/MDS_Final-Report_For-Publication_08222024.pdf
